Intra-Cellular Therapies has submitted a supplemental New Drug Application to the FDA for Caplyta (lumateperone) as an adjunct treatment for Major Depressive Disorder (MDD).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.